CH-EUS in Diagnosis of Inoperable Bile Duct Tumors
Contrast-enhanced Endoscopic Ultrasound in Diagnosis of Inoperable Bile Duct Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Rares-Ilie Orzan, PHD student
- Phone Number: +40727786221
- Email: orzanrares@gmail.com
Study Locations
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400394
- Recruiting
- IRGH "O. Fodor"
-
Contact:
- Rares Orzan, PHD student
- Phone Number: +40727786221
- Email: orzanrares@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Bile duct tumor diagnosed at endoscopic US, CT scan or MRI
- INR<1.5; platelets > 50.000
- written consent form
Exclusion Criteria:
- INR>1.5; platelets < 50.000
- duodenal invasion or stenosis
- patients denial
- previous treatment for hepato-biliary tumors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: EUS-FNA
|
Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
|
|
EXPERIMENTAL: CH-EUS-FNA
|
Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors
Time Frame: one week
|
To asses if CH-EUS FNB is superior to CH-EUS FNA when assessing bile duct tumors.
To determine the diagnostic accuracy, sensitivity and sensibility.
|
one week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Andrada Seicean, Professor, andradaseicean@gmail.com
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1509/03.02.2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.